Farallon Capital Management LLC Alnylam Pharmaceuticals, Inc. Transaction History

Farallon Capital Management LLC

$19.9 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $302,820 - $393,140	2,000 New	2,000 $382,000
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $341,540 - $423,300	2,000 New	2,000 $354,000
Q2 2023 Aug 14, 2023	SELL	$185.01 - $212.05 $873,062 - $1 Million	-4,719 Reduced 70.23%	2,000 $379,000
Q1 2023 May 15, 2023	SELL	$182.66 - $235.53 $22.5 Million - $29 Million	-123,337 Reduced 94.83%	6,719 $1.35 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $55.4 Million - $72 Million	-298,400 Reduced 69.65%	130,056 $30.9 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $49.8 Million - $83.4 Million	-359,454 Reduced 45.62%	428,456 $85.8 Million
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $28.4 Million - $39.9 Million	-235,963 Reduced 23.05%	787,910 $115 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $21.1 Million - $28.9 Million	-166,155 Reduced 13.96%	1,023,873 $167 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $60 Million - $78.6 Million	375,727 Added 46.14%	1,190,028 $202 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $23 Million - $28.2 Million	-135,699 Reduced 14.28%	814,301 $154 Million
Q2 2021 Aug 13, 2021	BUY	$128.63 - $176.89 $32.2 Million - $44.2 Million	250,000 Added 35.71%	950,000 $161 Million
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $44.4 Million - $61.5 Million	350,000 Added 100.0%	700,000 $98.8 Million
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $105 Million - $125 Million	-850,000 Reduced 70.83%	350,000 $45.5 Million
Q3 2020 Nov 16, 2020	BUY	$121.19 - $165.49 $18.2 Million - $24.8 Million	150,000 Added 14.29%	1,200,000 $175 Million
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $46.9 Million - $70.4 Million	-450,000 Reduced 30.0%	1,050,000 $156 Million
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $4.66 Million - $6.7 Million	50,000 Added 3.45%	1,500,000 $163 Million
Q4 2019 Feb 13, 2020	SELL	$74.51 - $124.23 $3.73 Million - $6.21 Million	-50,000 Reduced 3.33%	1,450,000 $167 Million
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $28.4 Million - $35.1 Million	400,000 Added 36.36%	1,500,000 $121 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $39.5 Million - $55.7 Million	600,000 Added 120.0%	1,100,000 $79.8 Million
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $3.64 Million - $4.67 Million	-50,000 Reduced 9.09%	500,000 $46.7 Million
Q4 2018 Feb 14, 2019	BUY	$62.67 - $88.33 $17.1 Million - $24.2 Million	273,449 Added 98.88%	550,000 $40.1 Million
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $12.1 Million - $17 Million	-138,449 Reduced 33.36%	276,551 $24.2 Million
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $3.97 Million - $4.85 Million	45,000 Added 12.16%	415,000 $40.9 Million
Q1 2018 May 15, 2018	BUY	$115.92 - $148.54 $42.9 Million - $55 Million	370,000 New	370,000 $44.1 Million

Others Institutions Holding ALNY

# of Institutions

642

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

Capital World Investors Los Angeles, CA

16.5M
Shares

$4.04 Billion
0.73% of portfolio
Vanguard Group Inc Valley Forge, PA

12.6M
Shares

$3.09 Billion
0.06% of portfolio
Black Rock Inc. New York, NY

9.55M
Shares

$2.34 Billion
0.05% of portfolio
Capital Research Global Investors Los Angeles, CA

5.24M
Shares

$1.28 Billion
0.31% of portfolio
Wellington Management Group LLP Boston, MA

4.95M
Shares

$1.21 Billion
0.24% of portfolio

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.

Account